The efficacy and safety of efgartigimod for refractory myasthenia gravis: a systematic review and meta-analysis.

ABSTRACT:

Background

Myasthenia gravis (MG) is a chronic autoimmune disorder affecting the neuromuscular junction, where autoreactive immunoglobulin G (IgG) plays a key role in disease pathogenesis. The novel biologic Efgartigimod is a neonatal Fc receptor (FcRn) antagonist, promotes the lysosomal degradation of IgG, and may offer a targeted approach for managing MG. Despite the growing interest in efgartigimod, there remains a lack of comprehensive evaluation of its efficacy and safety in different MG subtypes.

Methods

Comprehensive retrieval and screening were conducted on Pubmed, Embase, Web of Science, and Cochrane library to search studies on efgartigimod treatment. The data on response rates and adverse events were extracted, and the pooled effect size (ES) with the 95% confiden

SUBMITTER: Cheng JJ 

PROVIDER: S-EPMC12366048 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature